OBJECTIVE: To evaluate the outcomes and @entity137 of concurrent full-dose @entity136 and intensity-modulated radiation therapy (IMRT) for @entity1 with borderline resectable and locally advanced @entity788 after induction chemotherapy. MATERIALS AND METHODS: From 2009 to 2012, 32 @entity1 were treated with concurrent @entity136 and IMRT for borderline resectable or locally advanced @entity788 . All @entity1 received induction FOLFIRINOX or @entity136 -based chemotherapy before chemoradiation. The radiotherapy volume was limited to the @entity5 , and the median dose was 55 Gy in 25 fractions. @entity136 was administered weekly during radiotherapy on days 1, 8, 22, and 29 at a median weekly dose of 800 mg/m. RESULTS: Twenty-five @entity1 had locally advanced disease and 7 had borderline resectable disease. The median follow-up time was 14.6 months. The median progression-free and overall survival were 13.9 and 23.1 months, with a trend toward improved overall survival for @entity1 receiving induction FOLFIRINOX compared with @entity136 -based therapy. A radiographic complete or partial response was achieved in 13 @entity1 (41%), with 4 (13%) having complete radiographic responses. Surgical resection was performed in 10 @entity1 (31%)-6 @entity1 with locally advanced disease and 4 with borderline resectable disease. Grade 3/4 hematologic @entity137 during and up to 6 weeks after chemoradiation occurred in 12 @entity1 (38%); grade 3 nonhematologic @entity137 occurred in 7 @entity1 (22%), with no grade 4 or 5 @entity137 . All @entity1 completed their radiotherapy. CONCLUSIONS: Concurrent full-dose @entity136 and limited-field IMRT after induction chemotherapy for the treatment of borderline resectable and locally advanced @entity788 is promising with acceptable @entity137 rates.

Induction Chemotherapy Followed by Concurrent Full-dose XXXX and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced @entity788 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'pancreatic adenocarcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']
